Moreover, the differential expression pattern of PSMA, characterized by its overexpression in prostate cancer cells compared to normal prostate tissue, serves as a foundational basis for its utility in both diagnostic and therapeutic interventions. This evidence concerns the gene FOLH1 and prostate carcinoma.